GPR149

Summary

GPR149 (G protein-coupled receptor 149, HGNC:23627) is a protein-coding gene on chromosome 3q25.2, encoding Probable G-protein coupled receptor 149 (Q86SP6). Orphan receptor.

This gene encodes a seven-transmembrane G protein coupled receptor (GPCR) class A family member. Although categorized as a class A GPCR, the encoded protein lacks the first two charged amino acids of the highly conserved Asp-Arg-Tyr (DRY) motif found in the third transmembrane helix of class A receptors which is important for efficient G protein-coupled signal transduction. Mice with a knockout of the orthologous gene are viable and have normal maturation of the ovarian follicle, but show enhanced fertility and ovulation. All GPCRs have a common structural architecture consisting of seven transmembrane alpha-helices interconnected by three extracellular and three intracellular loops. A general feature of GPCR signaling is agonist-induced conformational changes in the receptor, leading to activation of the heterotrimeric G proteins, which consist of the guanine nucleotide-binding G-alpha subunit and the dimeric G-beta-gamma subunits. The activated G proteins then bind to and activate numerous downstream effector proteins, which generate second messengers that mediate a broad range of cellular and physiological processes.

Source: NCBI Gene 344758 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 122 total
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_001038705

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23627
Approved symbol	GPR149
Name	G protein-coupled receptor 149
Location	3q25.2
Locus type	gene with protein product
Status	Approved
Aliases	PGR10, IEDA, R35
Ensembl gene	ENSG00000174948
Ensembl biotype	protein_coding
Entrez	344758

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000389740

RefSeq mRNA: 1 — MANE Select: NM_001038705 NM_001038705

CCDS: CCDS43162

Canonical transcript exons

ENST00000389740 — 4 exons

Exon	Start	End
ENSE00001182662	154421039	154421487
ENSE00001182665	154427516	154427708
ENSE00001506778	154334943	154338271
ENSE00001506781	154428635	154430190

Expression profiles

Bgee: expression breadth broad, 26 present calls, max score 84.20.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4952 / max 66.5699, expressed in 85 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45213	0.3336	75
45211	0.1029	25
45212	0.0475	17
45214	0.0112	5

Top tissues by expression

122 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.20	silver quality
nucleus accumbens	UBERON:0001882	63.98	gold quality
caudate nucleus	UBERON:0001873	58.13	gold quality
putamen	UBERON:0001874	57.12	gold quality
adrenal tissue	UBERON:0018303	55.75	gold quality
pituitary gland	UBERON:0000007	53.70	gold quality
prefrontal cortex	UBERON:0000451	52.95	gold quality
superior frontal gyrus	UBERON:0002661	51.95	gold quality
adenohypophysis	UBERON:0002196	51.71	gold quality
hypothalamus	UBERON:0001898	50.31	gold quality
sural nerve	UBERON:0015488	48.06	gold quality
frontal cortex	UBERON:0001870	46.02	gold quality
brain	UBERON:0000955	44.86	gold quality
primary visual cortex	UBERON:0002436	43.20	silver quality
islet of Langerhans	UBERON:0000006	42.86	gold quality
anterior cingulate cortex	UBERON:0009835	42.69	gold quality
substantia nigra	UBERON:0002038	42.53	gold quality
cerebral cortex	UBERON:0000956	41.98	gold quality
Brodmann (1909) area 9	UBERON:0013540	41.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	41.04	gold quality
colonic epithelium	UBERON:0000397	41.00	gold quality
cortical plate	UBERON:0005343	39.95	gold quality
skeletal muscle tissue	UBERON:0001134	37.67	gold quality
muscle tissue	UBERON:0002385	37.60	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
endometrium	UBERON:0001295	35.14	gold quality
temporal lobe	UBERON:0001871	34.67	silver quality
apex of heart	UBERON:0002098	34.54	gold quality
amygdala	UBERON:0001876	34.42	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.45

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• Data revealed that hypermethylation of ZNF492 and GPR149 was significantly associated with shorter timetoprogression of patients with clear cell renal cell carcinoma (ccRCC). Hypermethylation of ZNF492 and GPR149 may be independent predictors of tumor progression. Similarly, the methylation status of these two genes was significantly associated with poor outcomes in the independent external validation cohort. (PMID:31115548)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gpr149	ENSMUSG00000043441
rattus_norvegicus	Gpr149	ENSRNOG00000014793
drosophila_melanogaster	Rh7	FBGN0036260
caenorhabditis_elegans	trhr-1	WBGENE00016265

Paralogs (17): OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038), KISS1R (ENSG00000116014), OPRD1 (ENSG00000116329), OPRL1 (ENSG00000125510), NPBWR2 (ENSG00000125522), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), UTS2R (ENSG00000181408), PTGDR2 (ENSG00000183134), CMKLR2 (ENSG00000183671), LTB4R (ENSG00000213903), LTB4R2 (ENSG00000213906), SSTR3 (ENSG00000278195), NPBWR1 (ENSG00000288611)

Protein

Protein identifiers

Probable G-protein coupled receptor 149 — Q86SP6 (reviewed: Q86SP6)

Alternative names: G-protein coupled receptor PGR10

All UniProt accessions (2): Q86SP6, Q2MKA6

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_001033794* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR017452	GPCR_Rhodpsn_7TM	Domain

UniProt features (24 total): topological domain 8, transmembrane region 7, glycosylation site 3, region of interest 2, compositionally biased region 2, chain 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86SP6-F1	54.04	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 105–182

Glycosylation sites (3): 7, 11, 21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 49 (showing top): GOBP_NEGATIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_GROWTH, GOBP_OOGENESIS, GOBP_OVARIAN_FOLLICLE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_OVULATION_CYCLE_PROCESS, GOBP_OVULATION, GOBP_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_FEMALE_SEX_DIFFERENTIATION, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_SEX_DIFFERENTIATION, GOBP_FEMALE_GAMETE_GENERATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOCC_NEURON_PROJECTION

GO Biological Process (6): preantral ovarian follicle growth (GO:0001546), antral ovarian follicle growth (GO:0001547), neuropeptide signaling pathway (GO:0007218), negative regulation of ovulation (GO:0060280), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), neuropeptide binding (GO:0042923)

GO Cellular Component (3): plasma membrane (GO:0005886), neuron projection (GO:0043005), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ovarian follicle development	2
ovulation cycle process	2
developmental growth	2
G protein-coupled receptor signaling pathway	2
multi-layer follicle stage	1
developmental process involved in reproduction	1
ovulation	1
negative regulation of multicellular organismal process	1
regulation of ovulation	1
negative regulation of reproductive process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
peptide binding	1
membrane	1
cell periphery	1
plasma membrane bounded cell projection	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR149	GPR139	Q6DWJ6	625
GPR149	GPR176	Q14439	492
GPR149	GPR151	Q8TDV0	462
GPR149	STK32A	Q8WU08	461
GPR149	ATP6AP1L	Q52LC2	450
GPR149	GPRC5C	Q9NQ84	447
GPR149	GPR153	Q6NV75	444
GPR149	PLEKHG1	Q9ULL1	441
GPR149	DHX36	Q9H2U1	441
GPR149	LRRC58	Q96CX6	422
GPR149	PPP4R4	Q6NUP7	413
GPR149	ZNF492	Q9P255	400
GPR149	GPR137C	Q8N3F9	398
GPR149	MAP7D3	Q8IWC1	396
GPR149	GPR108	Q9NPR9	393

IntAct

0 interactions, top by confidence:

BioGRID (1): GPR149 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GSN8, A0A1B0GSZ0, A0A1B0GWG4, A0JNM1, A2A2V5, A2APA5, A7E1Z1, A7MB05, A9CBA0, B0S728, F5HGU6, O39519, O44535, O88472, P02724, P02727, P0CAX8, P14221, P16742, P18345, P69338, P69339, Q02223, Q0VFL4, Q149F5, Q28913, Q2KIK3, Q2LCV6, Q2TAV2, Q498C7, Q5JX69, Q5R7R7, Q60664, Q68D42, Q68FB2, Q69569, Q6AYF7, Q7M750, Q80WK2, Q86SP6

Diamond homologs: Q3UVY1, Q86SP6, Q924Y8, Q9DDD1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

122 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	118
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2046 predictions. Top by Δscore:

Variant	Effect	Δscore
3:154360452:A:AC	donor_gain	1.0000
3:154338270:CG:C	acceptor_gain	0.9900
3:154338272:C:CC	acceptor_gain	0.9900
3:154360441:CAATT:C	donor_gain	0.9900
3:154360453:A:C	donor_gain	0.9900
3:154360477:A:AC	donor_gain	0.9900
3:154421488:C:CC	acceptor_gain	0.9900
3:154427514:A:AC	donor_gain	0.9900
3:154427515:C:CC	donor_gain	0.9900
3:154428924:T:TA	donor_gain	0.9900
3:154408993:TCC:T	donor_gain	0.9800
3:154421483:CTTGA:C	acceptor_gain	0.9800
3:154421492:G:GC	acceptor_gain	0.9800
3:154423538:T:C	donor_gain	0.9800
3:154428528:T:TA	donor_gain	0.9800
3:154428656:G:GT	donor_gain	0.9800
3:154428691:T:TA	donor_gain	0.9800
3:154339191:T:C	acceptor_gain	0.9700
3:154360448:A:AC	donor_gain	0.9700
3:154360449:C:CC	donor_gain	0.9700
3:154421034:TGTAC:T	donor_loss	0.9700
3:154421035:GTACC:G	donor_loss	0.9700
3:154421036:TACCT:T	donor_loss	0.9700
3:154421037:ACCT:A	donor_loss	0.9700
3:154421038:C:CA	donor_loss	0.9700
3:154421484:TTGA:T	acceptor_gain	0.9700
3:154428624:TG:T	donor_gain	0.9700
3:154428705:A:AC	donor_gain	0.9700
3:154428706:C:CC	donor_gain	0.9700
3:154408992:TTC:T	donor_gain	0.9600

AlphaMissense

4784 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:154337913:A:G	F661S	0.999
3:154337913:A:C	F661C	0.998
3:154337940:A:G	L652P	0.998
3:154337981:A:C	S638R	0.998
3:154337981:A:T	S638R	0.998
3:154337983:T:G	S638R	0.998
3:154337935:A:C	Y654D	0.997
3:154338186:A:G	L570P	0.997
3:154337912:A:C	F661L	0.996
3:154337912:A:T	F661L	0.996
3:154337914:A:G	F661L	0.996
3:154338039:A:G	L619S	0.996
3:154421074:A:G	W530R	0.996
3:154421074:A:T	W530R	0.996
3:154337932:A:G	S655P	0.995
3:154337988:A:T	I636N	0.995
3:154338192:A:G	L568P	0.995
3:154338229:C:A	G556W	0.995
3:154338229:C:G	G556R	0.995
3:154338229:C:T	G556R	0.995
3:154337745:A:G	L717S	0.994
3:154337937:C:G	R653P	0.994
3:154337982:C:A	S638I	0.994
3:154337988:A:C	I636S	0.994
3:154338045:A:G	I617T	0.994
3:154338045:A:T	I617K	0.994
3:154338186:A:T	L570H	0.994
3:154337829:A:G	I689T	0.993
3:154337874:A:G	L674P	0.993
3:154421072:C:A	W530C	0.993

dbSNP variants (sampled 300 via entrez): RS1000064598 (3:154392634 A>C), RS1000082250 (3:154396416 A>G), RS1000114511 (3:154409609 T>C), RS1000134779 (3:154396632 T>C), RS1000151949 (3:154426419 G>A), RS1000169969 (3:154430538 AAT>A), RS1000213371 (3:154426014 G>A,C,T), RS1000214849 (3:154361521 A>T), RS1000223670 (3:154347113 T>C), RS1000261052 (3:154402584 G>T), RS1000267073 (3:154426259 CAA>C), RS1000330978 (3:154373128 C>A,T), RS1000348163 (3:154389967 G>A), RS1000361075 (3:154415497 A>G), RS1000376406 (3:154375180 A>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): hypertrophic cardiomyopathy (MONDO:0005045)

Orphanet (1): Rare hypertrophic cardiomyopathy (Orphanet:217569)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001639	Hypertrophic cardiomyopathy

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST003720_38	Migraine	2.000000e-09
GCST005194_166	Coronary artery disease	4.000000e-14
GCST005195_18	Coronary artery disease	3.000000e-15
GCST007094_142	Diastolic blood pressure	3.000000e-13
GCST007099_22	Systolic blood pressure	4.000000e-12
GCST008360_4	Response to cognitive-behavioural therapy in anxiety disorder	4.000000e-06
GCST008830_12	Neurofibrillary tangles	2.000000e-06
GCST010241_428	Apolipoprotein A1 levels	4.000000e-12
GCST010242_382	HDL cholesterol levels	4.000000e-10
GCST011385_1	Vaginal microbiome composition (Shannon diversity index)	4.000000e-06
GCST011742_14	Triglyceride levels in HIV infection	7.000000e-06
GCST012489_12	Heel bone mineral density x serum urate levels interaction	4.000000e-11
GCST012490_387	Femur bone mineral density x serum urate levels interaction	4.000000e-08

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0007820	cognitive behavioural therapy
EFO:0006797	neurofibrillary tangles measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0011013	vaginal microbiome measurement
EFO:0004530	triglyceride measurement
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523883 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with no pharmacology

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases methylation, increases mutagenesis	2
Aflatoxin B1	decreases methylation	2
aflatoxin B2	increases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Copper	decreases expression, affects cotreatment	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883417	Binding	PRESTO-Tango GPCRome screening (GPR149)	Data for DCP probe UCSF924

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KX38	PathHunter CHO-K1 GPR149 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

227 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001960	PHASE2	COMPLETED	Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00011076	PHASE2	COMPLETED	Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00035386	PHASE2	COMPLETED	Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00430833	PHASE2	UNKNOWN	CHANCE - Candesartan in Hypertrophic Cardiomyopathy
NCT00500552	PHASE2	COMPLETED	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
NCT01150461	PHASE2	COMPLETED	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01230918	PHASE2	TERMINATED	Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
NCT01447654	PHASE2	COMPLETED	Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
NCT01696370	PHASE2	UNKNOWN	Trimetazidine Therapy in Hypertrophic Cardiomyopathy
NCT01912534	PHASE2	COMPLETED	Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
NCT02590809	PHASE2	COMPLETED	Hypertrophic Cardiomyopathy Symptom Release by BX1514M
NCT03496168	PHASE2	COMPLETED	Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03532802	PHASE2	COMPLETED	The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03832660	PHASE2	COMPLETED	Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
NCT04219826	PHASE2	COMPLETED	Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
NCT04426578	PHASE2	UNKNOWN	Role of Perhexiline in Hypertrophic Cardiomyopathy